ReviewCureus2024
Eye Axial Length: Is There a Protective Link to Diabetic Retinopathy?
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of ocular biometrics between diabetic and non-diabetic adults: a population-based study.Scientific reports · 2026Article
- Mechanistic insights into SOCS5-related DNA damage and cellular senescence in diabetic retinopathy.Cell death discovery · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness globally, particularly among working-age adults. As the prevalence of diabetes continues to rise, understanding factors that influence DR development and progression is increasingly important. Recent studies suggest a protective association between a longer axial length (AL) of the eye and the risk of DR, particularly in myopic individuals. This review explores the potential mechanisms underlying this relationship, including reduced retinal vascular density, altered retinal blood flow, and ocular biomechanics, which may collectively reduce the susceptibility of retinal tissues to hyperglycemic damage. However, limitations such as confounding factors, ethnic and genetic differences, and methodological challenges highlight the need for further research. This review aims to explore the relationship between AL and DR, examining the biological mechanisms that may underpin this association, summarizing the epidemiological evidence, discussing the clinical implications, and identifying directions for future research. Understanding the protective role of AL could have significant clinical suggestions, including more tailored screening intervals and personalized treatment approaches for DR. Future studies should focus on longitudinal analyses, mechanistic insights, and diverse populations to establish a clearer understanding of this relationship and its potential for novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.